The Zhitong Finance App learned that Peger Biopharmaceutical-B (02565) rose by more than 30% this morning to HK$5, with a current turnover of about HK$805.16,300.
According to the news, Peger Biotech's core product vipenatide injection (Pidacan®) has been approved for marketing by the State Drug Administration. As a GLP-1 receptor agonist administered once a week, this product has differentiated characteristics such as treatment at the outset and no dose titration required. The company previously reached an exclusive commercial cooperation with Tengrui Pharmaceutical in mainland China to continue to promote the commercialization of products in medical institutions and online channels.
It is worth noting that vilpenatide has entered the 2026 national health insurance catalogue adjustment related procedures. As the publication of a new round of national health insurance catalogues approaches, the progress of product medical insurance admission has attracted market attention. If successfully included in medical insurance, it is expected that patients' access to medication will be further improved and conditions will be created for subsequent commercialization.
Furthermore, the company continues to promote research and development of innovative drugs for next-generation metabolic diseases. Among them, the circular RNA project CR059 is dedicated to achieving long-term GLP-1 expression, and early studies have shown the potential to extend dosage intervals; the APGP6 project focuses on the differentiated treatment direction of fat loss and lean body weight retention during weight loss, providing new R&D reserves for the company's long-term layout in the field of metabolic diseases.